Isotype-specific secondary antibodies for improved signal detection
Offers an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.
Bio-Rad Laboratories has launched its isotype-specific secondary antibodies. This new range of recombinant monoclonal antibodies, directed against the three main mouse isotypes: IgG1, IgG2a, and IgG2b, offer improved signal detection and specificity in imaging, ELISA, flow cytometry, and western blotting.
Secondary antibodies are key components of antibody detection systems. The selection of an optimum secondary antibody can improve positive signals in addition to reducing false positive or negative staining. Recombinant monoclonal isotype-specific secondary antibodies detect individual isotypes, without species or isotype cross-reactivity, enabling multiple unlabeled mouse monoclonal antibodies of differing isotypes to be used simultaneously. This obviates the need to source secondary antibodies from other species. The isotype-specific antibodies offer an alternative to cross-adsorbed secondary antibodies when absolute specificity is required, for instance, during multiplexing or to prevent nonspecific background staining.
Bio-Rad’s recombinant monoclonal antibodies are generated using the Human Combinatorial Antibody Library (HuCAL) and CysDisplay, a proprietary method of phage display with guided selection methods to obtain highly targeted reagents. The recombinant production method also ensures consistent and secure supply.
“Recombinant human monoclonal antibodies are selected against epitopes unique to the isotype and offer significant advantages over traditional secondary antibodies,” said Tracey Long, Bio-Rad Marketing Manager, Life Science Group. “Bio-Rad’s recombinant monoclonal isotype-specific antibodies are easy to use and can be substituted for any secondary in the protocol without the need for extra steps,” she added.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...